Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.47 |
| ▸ | RAB9A | P51151 | 8/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.47 |
| ▸ | RELA | Q04206 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 7/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6473675 | 1.00 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL6473679 | 1.00 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL6474363 | 0.90 | PPARD (0.50) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL6474374 | 0.90 | PPARD (0.50) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL6474367 | 0.90 | PPARD (0.50) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL6473774 | 0.89 | PPARD (0.48) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL6473765 | 0.89 | PPARD (0.48) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL6473974 | 0.89 | PPARD (0.48) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL6475224 | 0.87 | PPARD (0.47) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL6475305 | 0.87 | PPARD (0.47) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6869967-B2 | Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives | NOVO NORDISK A/S (DK) | 2005-03-22 | — | — | US | claimed |
| EP-1414778-A1 | NOVEL VINYL CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ANTIDIABETICS ETC. | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | EP | claimed |
| US-20030139473-A1 | Novel compounds, their preparation and use | VTVX HOLDINGS II LLC | 2003-07-24 | — | — | US | claimed |
| WO-2003011807-A1 | NOVEL VINYL CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ANTIDIABETICS ETC. | NOVO NORDISK A/S (DK) | 2003-02-13 | — | — | WO | claimed |
| US-6869967-B2 | Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives | NOVO NORDISK A/S (DK) | 2005-03-22 | — | — | US | disclosed |
| EP-1414778-A1 | NOVEL VINYL CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ANTIDIABETICS ETC. | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | EP | disclosed |
| US-20030139473-A1 | Novel compounds, their preparation and use | VTVX HOLDINGS II LLC | 2003-07-24 | — | — | US | disclosed |
| WO-2003011807-A1 | NOVEL VINYL CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ANTIDIABETICS ETC. | NOVO NORDISK A/S (DK) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139473-A1 | Novel compounds, their preparation and use | PPARG, PPARD, PPARA | NPC1 546/4885RAB9A 2668/4885SMN1; SMN2 2744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.